Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsMiguel Sanmamed, MD, PhD
Assistant Professor AdjunctAbout
Research
Publications
2026
306P Real-world outcomes and determinants of immune-mediated pneumonitis in stage III NSCLC treated with durvalumab after chemoradiotherapy
Lorca A, Vilalta A, Ferrandez J, Muñoz M, Ortego M, Sunyer A, Alencastre A, Pangua-Irigaray P, Arango N, Gurpide A, Moreno M, Sanmamed M, Unanua N. 306P Real-world outcomes and determinants of immune-mediated pneumonitis in stage III NSCLC treated with durvalumab after chemoradiotherapy. ESMO Open 2026, 11: 106616. DOI: 10.1016/j.esmoop.2026.106616.Peer-Reviewed Original ResearchRadiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity
Marco S, Fernández M, Honorato B, Juanarena N, Sainz C, Andueza A, Gould D, Anderson S, de Andrea C, Domínguez P, Wong P, Vásquez C, Narinda I, Unzu C, Isola S, Tavira B, Ariz M, Camps G, Sanmamed M, Pardo J, Labiano S, Alonso M, Marco-Sanz J, Guruceaga E, Collantes M, Simón J, Peñuelas I, Fernández-Irigoyen J, Santamaría E, Prieto J, Dubrot J. Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. Cancer Cell 2026 PMID: 41875889, DOI: 10.1016/j.ccell.2026.02.013.Peer-Reviewed Original ResearchAdeno-associated vectorsTumor microenvironmentImmunostimulatory tumor microenvironmentSystemic antitumor immunitySystemic antitumor responseCombination of RTImmune-evasion mechanismsInduce IL-12Antitumor immunityFas-dependent mannerAntitumor responseImmunotherapy platformTumor transductionIrradiated tumorsEpigenetic modificationsImmunostimulatory cytokinesImmunosuppressive factorsControl of transgene expressionIL-12RadiotherapyTransgene expressionLocal deliveryImmune systemConcomitant inductionTumorAn ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression
Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Arriola E, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Wermke M. An ongoing phase 1 trial of obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression. Endocrine Abstracts 2026 DOI: 10.1530/endoabs.116.c1.Peer-Reviewed Original ResearchEfficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with genitourinary extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial.
Navarro-Gorro N, Capdevila J, Gambardella V, Kuboki Y, Alese O, Morgensztern D, Sayehli C, Sanmamed M, Studeny M, Bouzaggou M, Chen Z, Lifke V, Wolf J, Wermke M. Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with genitourinary extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial. Journal Of Clinical Oncology 2026, 44: 152-152. DOI: 10.1200/jco.2026.44.7_suppl.152.Peer-Reviewed Original ResearchDelta-like ligand 3Disease control ratePhase I dose-escalation trialExtrapulmonary neuroendocrine carcinomasCytokine release syndromeNeuroendocrine carcinomaImmune effector cell-associated neurotoxicity syndromeDose-escalation regimensT-cell engagersPhase I trialMedian DORRECIST v1.1ECOG PSDLL3 expressionI trialNeurotoxicity syndromeSafety profileTumor typesControl rateTumor cellsCytoplasmic stainingEfficacy dataSub-analysisDisease progressionInvestigator reviewReply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
Wermke M, Gambardella V, Kuboki Y, Felip E, Sanmamed M, Alese O, Sayehli C, Arriola E, Wolf J, Villaruz L, Bertulis J, Studeny M, Bouzaggou M, Fang X, Morgensztern D. Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond. Journal Of Clinical Oncology 2026, jco2502654. PMID: 41570262, DOI: 10.1200/jco-25-02654.Peer-Reviewed Original ResearchSafety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab.
Sanmamed M, de Andrea C, Ruiz-Guillamón D, Rodriguez-Ruiz M, Ortego I, Eguren-Santamaría I, Benito A, López-Janeiro A, Gonzalez Gomariz J, Villalba-Esparza M, Molina A, Krasko A, Ponz-Sarvise M, Lopez-Picazo J, Gomis G, Molero-Glez P, Alexandru R, Pérez-Domínguez P, Rodriguez I, Sánchez-Gregorio S, Perez-Gracia J, Melero I. Safety, Feasibility, and Pharmacodynamic Activity of Intratumoral Injections of the Agonist Anti-CD137 (4-1BB) mAb Urelumab in Combination with Nivolumab. Clinical Cancer Research 2026, 32: 1036-1045. PMID: 41543348, DOI: 10.1158/1078-0432.ccr-25-2502.Peer-Reviewed Original ResearchIntratumoral deliveryIntratumoral injectionAnti-CD137Associated with durable clinical benefitTumor-infiltrating CD8 T cellsPharmacodynamic activityPD-1/PD-L1 blockadeAgonistic anti-CD137Durable clinical benefitT lymphocyte densityDisease control rateDose-escalation cohortsT-cell-activating cytokinesCD8 T cellsFresh tumor biopsiesIntravenous nivolumabCD137 expressionTumor biopsiesSerial biopsyIntravenous dosePharmacodynamic changesPeripheral bloodClinical benefitT cellsSolid tumors
2025
Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic
Eguren-Santamaria I, Melero I, Rodríguez I, Ortego I, Armero M, Galvez-Cancino F, López-Janeiro A, De Andrea C, Sanmamed M. Preclinical ex vivo and in vivo models to study immunotherapy agents and their combinations as predictive tools toward the clinic. Journal For ImmunoTherapy Of Cancer 2025, 13: e011279. PMID: 41161818, PMCID: PMC12574409, DOI: 10.1136/jitc-2024-011279.Peer-Reviewed Original ResearchConceptsHumanized mouse modelMouse modelImmunotherapy agentsClinical trialsHuman cancersFeatures of human cancersCancer immunotherapy applicationsPreclinical experimental modelsIn vivo modelsImmunotherapy interventionsPreclinical modelsPreclinical resultsClinical failureImmune cellsClinical developmentImmunotherapyImmunotherapy applicationsAnticancer treatmentHuman tumorsTherapeutic strategiesPreclinical researchEx vivoHuman specimensCancerExperimental modelBrief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
Di Frisco M, Sanmamed M, Ferrández J, Vilalta A, Sogbe M, García-Goñi M, Martin-Palmero Á, Aso-González S, Nadal E, Signes-Costa J, Gambardella V, Seguí Manzaneque V, Martin P, Insa A, Franco J, Lores C, de Torres J. Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors. Journal Of Thoracic Oncology 2025, 21: 328-333. PMID: 41130410, DOI: 10.1016/j.jtho.2025.10.007.Peer-Reviewed Original ResearchImmune checkpoint inhibitorsChronic obstructive pulmonary diseaseAdvanced NSCLCChest Computed TomographyOverall survivalCheckpoint inhibitorsPrognostic factorsNSCLC treated with immune checkpoint inhibitorsSingle-agent immune checkpoint inhibitorsAssociated with longer overall survivalAdvanced NSCLC patientsProgression-free survivalSecond-line treatmentLonger overall survivalAdverse event ratesLung cancer developmentObstructive pulmonary diseaseEmphysema statusNSCLC patientsPrognostic markerMultivariate analysisCancer developmentPulmonary diseasePatientsRisk factorsCN156 Research outcomes of a translational research unit coordinated by nursing
Andueza M, Ocon M, Zabalza E, Barberena Y, Burgui M, Perea A, Andueza I, Ilundain I, Andueza M, RodrÍguez-Ruiz M, Sanmamed M, Eslava M, Hernandez A, Fortuño M, de Torres J, Maceiras L, Lozano M, Melero I, Montuenga L, Gracia J. CN156 Research outcomes of a translational research unit coordinated by nursing. Annals Of Oncology 2025, 36: s1668-s1669. DOI: 10.1016/j.annonc.2025.08.1229.Peer-Reviewed Original ResearchAssociation of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients
de Andrea C, Abengozar-Muela M, Arranz J, Climent M, Puente J, Vizcay Á, de la Fuente L, Jurado J, Bonfill T, Santander C, Villa J, Pujol E, Rosero A, Gomez J, Fernández E, Fernández C, Ramirez I, Arnáiz P, López-Janeiro Á, Melero I, Sanmamed M, Pérez-Gracia J. Association of PD-1, LAG-3 and TIM-3 expression on intratumoral CD8 T-cells with response to atezolizumab in a Real-World-Evidence biomarker study for advanced urothelial carcinoma patients. OncoImmunology 2025, 14: 2538687. PMID: 40778981, PMCID: PMC12952735, DOI: 10.1080/2162402x.2025.2538687.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntigens, CDBiomarkers, TumorCD8-Positive T-LymphocytesFemaleHepatitis A Virus Cellular Receptor 2HumansLymphocyte Activation Gene 3 ProteinMaleMiddle AgedProgrammed Cell Death 1 ReceptorTumor MicroenvironmentUrinary Bladder NeoplasmsConceptsAdvanced urothelial cancerMultiplexed quantitative immunofluorescenceTumor microenvironmentT cellsClinical efficacyPD-1LAG-3Tim-3Urothelial cancerPredictive biomarkersReal-world evidenceDistribution of CD8+ T cellsQuantitative immunofluorescenceCD8+ T-cell densityAdvanced urothelial carcinoma patientsAssociation of PD-1Intratumoral CD8 T cellsPatients treated with atezolizumabPre-treatment tumor samplesCD8+ T cellsPD-1/PD-L1 pathwayHundred-nine patientsPD-L1 blockadeResponse to atezolizumabCD8 T cells